Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma The PROACT Clinical Trial

被引：5

作者：

Austin, David ^{[1
,2
]}

Maier, Rebecca H. ^{[1
,2
]}

Akhter, Nasima ^{[3
]}

Sayari, Mohammad ^{[4
]}

Ogundimu, Emmanuel ^{[4
]}

Maddox, Jamie M. ^{[5
]}

Vahabi, Sharareh ^{[6
]}

Humphreys, Alison C. ^{[7
]}

Graham, Janine ^{[7
,8
]}

Oxenham, Helen ^{[9
]}

Haney, Sophie ^{[7
,10
]}

Cresti, Nicola ^{[11
]}

Verrill, Mark ^{[11
]}

Osborne, Wendy ^{[11
]}

Wright, Kathryn L. ^{[11
,12
]}

Goranova, Rebecca ^{[13
]}

Bailey, James R. ^{[14
]}

Kalakonda, Nagesh ^{[15
]}

Macheta, Mac ^{[16
]}

Kilner, Mari F. ^{[17
]}

Young, Moya E. ^{[18
]}

Morley, Nick J. ^{[19
]}

Neelakantan, Pratap ^{[20
]}

Gilbert, Georgia ^{[1
]}

Thomas, Byju K. ^{[1
]}

Graham, Richard J. ^{[1
]}

Fujisawa, Takeshi ^{[21
]}

Mills, Nicholas L. ^{[21
]}

Hildreth, Victoria ^{[22
]}

Prichard, Jonathan ^{[22
]}

Kasim, Adetayo S. ^{[23
]}

Hancock, Helen C.

Plummer, Chris ^{[24
,25
]}

机构：

[1] South Tees Hosp NHS Fdn Trust, James Cook Univ Hosp, Acad Cardiovasc Unit, Marton Rd, Middlesbrough TS4 3BW, England

[2] Newcastle Univ, Populat Hlth Sci Inst, Newcastle Upon Tyne, England

[3] Teesside Univ, Sch Hlth & Life Sci, Middlesbrough, England

[4] Univ Durham, Durham Coll, Durham, England

[5] Teesside Univ, Dept Psychol, Middlesbrough TS1 3BX, England

[6] Univ Hosp Bristol & Weston NHS Fdn Trust, Bristol Heart Inst, Bristol, England

[7] South Tees Hosp NHS Fdn Trust, Middlesbrough, England

[8] North Tees & Hartlepool NHS Fdn Trust, Stockton On Tees, England

[9] North Tees & Hartlepool NHS Fdn Trust, Stockton On Tees, England

[10] Cty Durham & Darlington NHS Fdn Trust, Darlington, England

[11] Newcastle Upon Tyne Hosp NHS Fdn Trust, Freeman Hosp, Newcastle Upon Tyne, England

[12] South Tyneside & Sunderland NHS Fdn Trust, Sunderland, England

[13] Univ Hosp Plymouth NHS Trust, Derriford Hosp, Dept Microbiol, Plymouth, England

[14] Hull Univ Teaching Hosp NHS Trust, Castle Hill Hosp, Queens Ctr Oncol & Haematol, Dept Haematol, Kingston Upon Hull, England

[15] Univ Liverpool, Dept Mol & Clin Canc Med, Liverpool, England

[16] Blackpool Teaching Hosp, Dept Haematol, Blackpool, England

[17] Northumbria Healthcare NHS Fdn Trust, Pathol Serv, North Shields, England

[18] East Kent Hosp Univ NHS Fdn Trust, Dept Haematol, Canterbury, England

[19] Sheffield Teaching Hosp NHS Fdn Trust, Dept Haematol, Sheffield, England

[20] Royal Berkshire NHS Fdn Trust, Radiol Dept, Reading, England

[21] Univ Edinburgh, Ctr Cardiovasc Sci, Edinburgh, Scotland

[22] Newcastle Univ, Newcastle Clin Trials Unit, Newcastle Upon Tyne, England

[23] Univ Durham, Dept Anthropol, Durham, England

[24] Newcastle Upon Tyne NHS Fdn Trust, Dept Cardiol, Newcastle Upon Tyne, England

[25] Newcastle Univ, Fac Med Sci, Newcastle Upon Tyne, England

来源：

JACC: CARDIOONCOLOGY | 2024年 / 6卷 / 05期

关键词：

anthracycline; biomarkers; breast cancer; echocardiography; lymphoma; prevention; INDUCED CARDIOTOXICITY; DYSFUNCTION; ENALAPRIL; DOXORUBICIN; INHIBITION; TOXICITY; THERAPY;

D O I：

10.1016/j.jaccao.2024.07.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background Cardiotoxicity is a concern for cancer survivors undergoing anthracycline chemotherapy. Enalapril has been explored for its potential to mitigate cardiotoxicity in cancer patients. The dose-dependent cardiotoxicity effects of anthracyclines can be detected early through the biomarker cardiac troponin. Objectives The PROACT (Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma) clinical trial assessed the effectiveness of enalapril in preventing cardiotoxicity, manifesting as myocardial injury and cardiac function impairment, in patients undergoing high-dose anthracycline-based chemotherapy for breast cancer or non-Hodgkin lymphoma. Methods This prospective, multicenter, open-label, randomized controlled trial employed a superiority design with observer-blinded endpoints. A total of 111 participants, scheduled for 6 cycles of chemotherapy with a planned dose of >= 300 mg/m(2) doxorubicin equivalents, were randomized to receive either enalapril (titrated up to 20 mg daily) or standard care without enalapril. Results Myocardial injury, indicated by cardiac troponin T (>= 14 ng/L), during and 1 month after chemotherapy, was observed in 42 (77.8%) of 54 patients in the enalapril group vs 45 (83.3%) of 54 patients in the standard care group (OR: 0.65; 95% CI: 0.23-1.78). Injury detected by cardiac troponin I (>26.2 ng/L) occurred in 25 (47.2%) of 53 patients on enalapril compared with 24 (45.3%) of 53 in standard care (OR: 1.10; 95% CI: 0.50-2.38). A relative decline of more than 15% from baseline in left ventricular global longitudinal strain was observed in 10 (21.3%) of 47 patients on enalapril and 9 (21.9%) of 41 in standard care (OR: 0.95; 95% CI: 0.33-2.74). An absolute decline of >10% to <50% in left ventricular ejection fraction was seen in 2 (4.1%) of 49 patients on enalapril vs none in patients in standard care. Conclusions Adding enalapril to standard care during chemotherapy did not prevent cardiotoxicity in patients receiving high-dose anthracycline-based chemotherapy. (PROACT: Can we prevent Chemotherapy-related Heart Damage in Patients With Breast Cancer and Lymphoma?; NCT03265574)

引用

页码：684 / 696

页数：13

共 50 条

[21] Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
Yu, Anthony F.
Manrique, Carlos
Pun, Shawn
Liu, Jennifer E.
Mara, Elton
Fleisher, Amartin
Patil, Sujata
Jones, Lee W.
Steingart, Richard M.
Hudis, Clifford A.
Dang, Chau T.
ONCOLOGIST, 2016, 21 (04) : 418 - 424
[22] Usefulness of Myocardial Deformation Indices in Preventing Cardiotoxicity in Breast Cancer Patients
Tavares de Melo, Marcelo Dantas
Cury Salemi, Vera Maria
ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2019, 112 (01) : 57 - 58
[23] PET/CT in Patients with Breast Cancer Treated with Immunotherapy
Vaz, Sofia C.
Graff, Stephanie L.
Ferreira, Arlindo R.
Debiasi, Marcio
de Geus-Oei, Lioe-Fee
CANCERS, 2023, 15 (09)
[24] Cardiology Involvement in Patients With Breast Cancer Treated With Trastuzumab
Demissei, Biniyam G.
Adusumalli, Srinath
Hubbard, Rebecca A.
Denduluri, Srinivas
Narayan, Vivek
Clark, Amy S.
Shah, Payal
Knollman, Hayley
Getz, Kelly D.
Aplenc, Richard
Carver, Joseph R.
Ky, Bonnie
JACC: CARDIOONCOLOGY, 2020, 2 (02): : 179 - 189
[25] CBR3 V244M is associated with LVEF reduction in breast cancer patients treated with doxorubicin
Lang, Jennifer K.
Karthikeyan, Badri
Quinones-Lombrana, Adolfo
Blair, Rachael Hageman
Early, Amy P.
Levine, Ellis G.
Sharma, Umesh C.
Blanco, Javier G.
O'Connor, Tracey
CARDIO-ONCOLOGY, 2021, 7 (01)
[26] Soluble urokinase plasminogen activator receptor and cardiotoxicity in doxorubicin-treated breast cancer patients: a prospective exploratory study
Chu, Jian
Tung, Lillian
Attalah, Issam
Wei, Changli
Cobleigh, Melody
Rao, Ruta
Feinstein, Steven B.
Usha, Lydia
Banach, Kathrin
Reiser, Jochen
Okwuosa, Tochukwu M.
CARDIO-ONCOLOGY, 2024, 10 (01)
[27] Dexrazoxane improves cardiac autonomic function in epirubicin-treated breast cancer patients with type 2 diabetes
Sun, Fangyi
Shi, Jing
Geng, Cuizhi
MEDICINE, 2016, 95 (44)
[28] Cardiac safety of systemic therapy in breast cancer patients with high risk of atherosclerosis complications
Matyszewski, Arthur
Czarnecka, Anna M.
Stachowiak, Pawel
Nowakowska, Marta
Kornacewicz-Jach, Zdzislawa
Kasprzak, Jaroslaw D.
Szczylik, Cezary
FUTURE ONCOLOGY, 2017, 13 (07) : 593 - 602
[29] Breast cancer surveillance in patients treated by radiotherapy for Hodgkin's lymphoma
Mariscotti, G.
Durando, M.
Ghione, G.
Luparia, A.
Regini, E.
Alfieri, C.
Campanino, P. P.
Gavarotti, P.
Brignardello, E.
Gandini, G.
RADIOLOGIA MEDICA, 2013, 118 (03): : 401 - 414
[30] Impact of Arterial Hypertension on Doxorubicin-Based Chemotherapy-Induced Subclinical Cardiac Damage in Breast Cancer Patients
Vaitiekus, Domas
Muckiene, Gintare
Vaitiekiene, Audrone
Maciuliene, Dainora
Vaiciuliene, Dovile
Ambrazeviciute, Grete
Sereikaite, Liveta
Verikas, Dovydas
Jurkevicius, Renaldas
Juozaityte, Elona
CARDIOVASCULAR TOXICOLOGY, 2020, 20 (03) : 321 - 327

← 1 2 3 4 5 →